{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:57:43Z","timestamp":1760821063539},"reference-count":185,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"AbbVie Corp"},{"name":"Janssen Inc"},{"name":"Pfizer Canada Inc"},{"name":"Takeda Canada Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background &amp; Aims<\/jats:title>\n                  <jats:p>Crohn\u2019s disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms have been developed. We provide guidance for treatment of ambulatory patients with mild to severe active luminal CD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a systematic review to identify published studies of the management of CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a group of specialists.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The consensus includes 41 statements focused on 6 main drug classes: antibiotics, 5-aminosalicylate, corticosteroids, immunosuppressants, biologic therapies, and other therapies. The group suggested against the use of antibiotics or 5-aminosalicylate as induction or maintenance therapies. Corticosteroid therapies (including budesonide) can be used as induction, but not maintenance therapies. Among immunosuppressants, thiopurines should not be used for induction, but can be used for maintenance therapy for selected low-risk patients. Parenteral methotrexate was proposed for induction and maintenance therapy in patients with corticosteroid-dependent CD. Biologic agents, including tumor necrosis factor antagonists, vedolizumab, and ustekinumab, were recommended for patients failed by conventional induction therapies and as maintenance therapy. The consensus group was unable to clearly define the role of concomitant immunosuppressant therapies in initiation of treatment with a biologic agent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Optimal management of CD requires careful patient assessment, acknowledgement of patient preferences, evidence-based use of existing therapies, and thorough assessment to define treatment success.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jcag\/gwz019","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T14:46:01Z","timestamp":1562769961000},"page":"e1-e34","source":"Crossref","is-referenced-by-count":33,"title":["Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn\u2019s Disease"],"prefix":"10.1093","volume":"2","author":[{"given":"Remo","family":"Panaccione","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A Hillary","family":"Steinhart","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Bressler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, St Paul\u2019s Hospital, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Western Ontario, London, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K","family":"Marshall","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Targownik","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waqqas","family":"Afif","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Bitton","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Borgaonkar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Memorial University, St John\u2019s, Newfoundland, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usha","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Hamilton Health Sciences, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Halloran","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Division of General Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grigorios I","family":"Leontiadis","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Edward V","family":"Loftus","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Meddings","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Moayyedi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Murthy","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Plamondon","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Pacific Gastroenterology Associates, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Vanderbilt University, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia H","family":"Seow","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chadwick","family":"Williams","sequence":"additional","affiliation":[{"name":"Hilyard Place, Saint John, New Brunswick, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles N","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology, University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"2019071010454862800_CIT0001","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.3748\/wjg.v21.i23.7272","article-title":"Prevalence and predictors of hospitalization in Crohn\u2019s disease in a prospective population-based inception cohort from 2000\u20132012","volume":"21","author":"Golovics","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2019071010454862800_CIT0002","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/MIB.0000000000000608","article-title":"Mortality trends in Crohn\u2019s disease and ulcerative colitis: a population-based study in Quebec, Canada","volume":"22","author":"Bitton","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0003","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10620-014-3368-z","article-title":"The economic and quality-of-life burden of Crohn\u2019s disease in Europe and the United States, 2000 to 2013: a systematic review","volume":"60","author":"Floyd","year":"2015","journal-title":"Dig Dis Sci"},{"key":"2019071010454862800_CIT0004","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.13475","article-title":"Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn\u2019s disease","volume":"43","author":"Shah","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2019071010454862800_CIT0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/apt.13276","article-title":"Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy","volume":"42","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2019071010454862800_CIT0006","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0007","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11136-016-1398-z","article-title":"Value redefined for inflammatory bowel disease patients: a choice-based conjoint analysis of patients\u2019 preferences","volume":"26","author":"van Deen","year":"2017","journal-title":"Qual Life Res"},{"key":"2019071010454862800_CIT0008","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/ajg.2015.321","article-title":"Inflammatory bowel disease patients\u2019 willingness to accept medication risk to avoid future disease relapse","volume":"110","author":"Bewtra","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"key":"2019071010454862800_CIT0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1\u2014diagnosis and medical management","volume":"11","author":"Gomollon","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019071010454862800_CIT0011","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2019071010454862800_CIT0012","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cgh.2013.02.001","article-title":"The AGA institute process for developing clinical practice guidelines part one: grading the evidence","volume":"11","author":"Sultan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0013","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","article-title":"Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus","volume":"148","author":"Bressler","year":"2015","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0014","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2014.01.042","article-title":"Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology","volume":"146","author":"Nguyen","year":"2014","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto consensus for the treatment of Helicobacter pylori infection in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0016","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0017","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jclinepi.2014.12.011","article-title":"Guideline panels should not GRADE good practice statements","volume":"68","author":"Guyatt","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"2019071010454862800_CIT0018","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0016-3287(69)80025-X","article-title":"An experimental study of group opinion: the Delphi method","volume":"1","author":"Dalkey","year":"1969","journal-title":"Futures"},{"key":"2019071010454862800_CIT0019","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7326\/0003-4819-127-3-199708010-00006","article-title":"The relation between systematic reviews and practice guidelines","volume":"127","author":"Cook","year":"1997","journal-title":"Ann Intern Med"},{"key":"2019071010454862800_CIT0020","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2019071010454862800_CIT0021","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"2019071010454862800_CIT0022","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/j.gastro.2014.08.003","article-title":"Converging goals of treatment of inflammatory bowel disease from clinical trials and practice","volume":"148","author":"Levesque","year":"2015","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn\u2019s disease activity index: National Cooperative Crohn\u2019s Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0024","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/gut.35.2.231","article-title":"Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn\u2019s disease: a prospective multicentre study of 121 cases\u2014The Groupe d\u2019Etudes Therapeutiques des Affections Inflammatoires Digestives","volume":"35","author":"Cellier","year":"1994","journal-title":"Gut"},{"key":"2019071010454862800_CIT0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ibd.20312","article-title":"Crohn\u2019s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn\u2019s disease activity index and endoscopic findings","volume":"14","author":"Sipponen","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0026","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.cgh.2008.06.010","article-title":"Relationships between disease activity and serum and fecal biomarkers in patients with Crohn\u2019s disease","volume":"6","author":"Jones","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0027","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","article-title":"Correlation between the Crohn\u2019s disease activity and Harvey-Bradshaw indices in assessing Crohn\u2019s disease severity","volume":"8","author":"Vermeire","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0028","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"2019071010454862800_CIT0029","first-page":"543","article-title":"Development of the Harvey-Bradshaw Index-pro (HBI-PRO) score to assess endoscopic disease activity in Crohn\u2019s disease","volume":"5","author":"Zittan","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019071010454862800_CIT0030","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/gutjnl-2016-312648","article-title":"Development of an index to define overall disease severity in IBD","volume":"67","author":"Siegel","year":"2018","journal-title":"Gut"},{"key":"2019071010454862800_CIT0031","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1053\/j.gastro.2005.12.019","article-title":"Predictors of Crohn\u2019s disease","volume":"130","author":"Beaugerie","year":"2006","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0032","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1080\/00365520801957149","article-title":"Predictors of severe Crohn\u2019s disease","volume":"43","author":"Loly","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"2019071010454862800_CIT0033","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.3748\/wjg.v18.i29.3806","article-title":"Clinical, serological and genetic predictors of inflammatory bowel disease course","volume":"18","author":"Beaugerie","year":"2012","journal-title":"World J Gastroenterol"},{"key":"2019071010454862800_CIT0034","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/ibd.21933","article-title":"High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn\u2019s disease: a marker for patient classification?","volume":"18","author":"Kiss","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0035","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/ibd.22861","article-title":"Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies","volume":"18","author":"Mao","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0036","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1097\/MIB.0000000000000894","article-title":"High vitamin D-binding protein concentration, low albumin, and mode of remission predict relapse in Crohn\u2019s disease","volume":"22","author":"Ghaly","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0037","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.12659\/MSM.897460","article-title":"Serum albumin and C-reactive protein\/albumin ratio are useful biomarkers of Crohn\u2019s disease activity","volume":"22","author":"Qin","year":"2016","journal-title":"Med Sci Monit"},{"key":"2019071010454862800_CIT0038","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/apt.13001","article-title":"A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn\u2019s disease activity","volume":"41","author":"Khanna","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2019071010454862800_CIT0039","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/S1873-9946(14)60297-X","article-title":"Patient reported outcome measures derived from the Crohn\u2019s Disease Activity Index: correlation between PRO2 and PRO3 scores and CDAI-defined clinical thresholds [abstract P176]","volume":"8","author":"Khanna","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2019071010454862800_CIT0040","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","article-title":"Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn\u2019s disease","volume":"138","author":"Baert","year":"2010","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0041","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ibd.20927","article-title":"Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn\u2019s disease","volume":"15","author":"Schnitzler","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0042","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn\u2019s disease","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"2019071010454862800_CIT0043","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cgh.2013.09.006","article-title":"Treat to target: a proposed new paradigm for the management of Crohn\u2019s disease","volume":"13","author":"Bouguen","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0044","volume-title":"Enhanced agorithm for Crohn\u2019s treatment incorporating early combination therapy (REACT-2)"},{"key":"2019071010454862800_CIT0045","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/MIB.0b013e318283a4b3","article-title":"Evolving definitions of remission in Crohn\u2019s disease","volume":"19","author":"Panaccione","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0046","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/gutjnl-2015-309903","article-title":"IOIBD technical review on endoscopic indices for Crohn\u2019s disease clinical trials","volume":"65","author":"Vuitton","year":"2016","journal-title":"Gut"},{"key":"2019071010454862800_CIT0047","first-page":"CD010642","article-title":"Endoscopic scoring indices for evaluation of disease activity in Crohn\u2019s disease","author":"Khanna","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0048","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/ajg.2016.177","article-title":"Radiological response is associated with better long-term outcomes and is a potential treatment target in patients with small bowel Crohn\u2019s disease","volume":"111","author":"Deepak","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0049","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1007\/s00330-015-3737-9","article-title":"Grading of Crohn\u2019s disease activity using CT, MRI, US and scintigraphy: a meta-analysis","volume":"25","author":"Puylaert","year":"2015","journal-title":"Eur Radiol"},{"key":"2019071010454862800_CIT0050","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1007\/s00330-009-1423-5","article-title":"Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn\u2019s disease: CT findings and correlation with endoscopy","volume":"19","author":"Minordi","year":"2009","journal-title":"Eur Radiol"},{"key":"2019071010454862800_CIT0051","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00261-015-0360-9","article-title":"CT and MR enterography in Crohn\u2019s disease: current and future applications","volume":"40","author":"Bruining","year":"2015","journal-title":"Abdom Imaging"},{"key":"2019071010454862800_CIT0052","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.ejrad.2011.07.013","article-title":"Non-perforating small bowel Crohn\u2019s disease assessed by MRI enterography: derivation and histopathological validation of an MR-based activity index","volume":"81","author":"Steward","year":"2012","journal-title":"Eur J Radiol"},{"key":"2019071010454862800_CIT0053","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/gut.2008.167957","article-title":"Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn\u2019s disease","volume":"58","author":"Rimola","year":"2009","journal-title":"Gut"},{"key":"2019071010454862800_CIT0054","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.dld.2016.09.009","article-title":"Patient preferences for inflammatory bowel disease treatment objectives","volume":"49","author":"Casellas","year":"2017","journal-title":"Dig Liver Dis"},{"key":"2019071010454862800_CIT0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/PPA.S32690","article-title":"Patient perspectives on the impact of Crohn\u2019s disease: results from group interviews","volume":"6","author":"Norton","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"2019071010454862800_CIT0056","first-page":"947","article-title":"Long term outcome of patients with active Crohn\u2019s disease exhibiting extensive and deep ulcerations at colonoscopy","volume":"97","author":"Allez","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0057","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/gutjnl-2012-303957","article-title":"Role of endoscopy, cross-sectional imaging and biomarkers in Crohn\u2019s disease monitoring","volume":"62","author":"Benitez","year":"2013","journal-title":"Gut"},{"key":"2019071010454862800_CIT0058","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nrgastro.2016.128","article-title":"Current best practice for disease activity assessment in IBD","volume":"13","author":"Walsh","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0059","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining disease severity in inflammatory bowel diseases: current and future directions","volume":"14","author":"Peyrin-Biroulet","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0060","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.gastro.2016.10.005","article-title":"Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases","volume":"152","author":"Panes","year":"2017","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0061","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ajg.2011.72","article-title":"Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis","volume":"106","author":"Khan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0062","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/1751-2980.12216","article-title":"Use of antibiotics in patients with Crohn\u2019s disease: a systematic review and meta-analysis","volume":"16","author":"Su","year":"2015","journal-title":"J Dig Dis"},{"key":"2019071010454862800_CIT0063","first-page":"CD000299","article-title":"Anti-tuberculous therapy for maintenance of remission in Crohn\u2019s disease","author":"Patton","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0064","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/gutjnl-2013-304488","article-title":"Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn\u2019s disease: a randomised, double-blind, placebo controlled trial (ADAFI)","volume":"63","author":"Dewint","year":"2014","journal-title":"Gut"},{"key":"2019071010454862800_CIT0065","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ajg.2011.71","article-title":"Efficacy of 5-aminosalicylates in Crohn\u2019s disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0066","first-page":"CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn\u2019s disease","author":"Lim","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0067","first-page":"CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn\u2019s disease","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0068","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn\u2019s Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0069","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn\u2019s Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0070","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00054725-200108000-00007","article-title":"Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine","volume":"7","author":"Naganuma","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0071","first-page":"917","article-title":"The effect of sulfasalazine and 5-aminosalicylic acid on the secretion of interleukin 8 by human colon myofibroblasts","volume":"72","author":"Lodowska","year":"2015","journal-title":"Acta Pol Pharm"},{"key":"2019071010454862800_CIT0072","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.22.5.404","article-title":"Effect of sulphasalazine in patients with active Crohn\u2019s disease: a controlled double-blind study","volume":"22","author":"Van Hees","year":"1981","journal-title":"Gut"},{"key":"2019071010454862800_CIT0073","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/apt.13190","article-title":"Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn\u2019s disease","volume":"41","author":"Moja","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2019071010454862800_CIT0074","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/ajg.2011.70","article-title":"Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0075","first-page":"CD000296","article-title":"Budesonide for induction of remission in Crohn\u2019s disease","author":"Rezaie","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0076","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.crohns.2014.01.021","article-title":"Once versus three times daily dosing of oral budesonide for active Crohn\u2019s disease: a double-blind, double-dummy, randomised trial","volume":"8","author":"Dignass","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2019071010454862800_CIT0077","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.crohns.2012.06.006","article-title":"Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn\u2019s disease: a multicentre, double-blind, randomized, parallel-group Phase II study","volume":"7","author":"Suzuki","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2019071010454862800_CIT0078","first-page":"CD002913","article-title":"Budesonide for maintenance of remission in Crohn\u2019s disease","author":"Kuenzig","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0079","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-2036.2008.03891.x","article-title":"Oral budesonide for maintenance of remission of Crohn\u2019s disease: a pooled safety analysis","volume":"29","author":"Lichtenstein","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"2019071010454862800_CIT0080","first-page":"CD006792","article-title":"Traditional corticosteroids for induction of remission in Crohn\u2019s disease","author":"Benchimol","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0081","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1572-0241.2002.05596.x","article-title":"Corticosteroids in Crohn\u2019s disease","volume":"97","author":"Yang","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0082","first-page":"CD000952","article-title":"Calcium and vitamin D for corticosteroid-induced osteoporosis","author":"Homik","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0083","first-page":"905","article-title":"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn\u2019s disease: German\/Austrian Budesonide Study Group","volume":"8","author":"Gross","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0084","first-page":"PI29","article-title":"Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn\u2019s disease: an open-label, budesonide-controlled, randomized study","volume":"12","author":"Tursi","year":"2006","journal-title":"Med Sci Monit"},{"key":"2019071010454862800_CIT0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00054725-199808000-00001","article-title":"Intravenous corticotrophin vs hydrocortisone in the treatment of hospitalized patients with Crohn\u2019s disease: a randomized double-blind study and follow-up","volume":"4","author":"Chun","year":"1998","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0086","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00004836-198604000-00010","article-title":"Use of an intravenous steroid regimen in the treatment of acute Crohn\u2019s disease","volume":"8","author":"Shepherd","year":"1986","journal-title":"J Clin Gastroenterol"},{"key":"2019071010454862800_CIT0087","first-page":"CD000301","article-title":"Corticosteroids for maintenance of remission in Crohn\u2019s disease","author":"Steinhart","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0088","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1542-3565(04)00662-7","article-title":"Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn\u2019s disease","volume":"3","author":"Schoon","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0089","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","article-title":"American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0090","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0091","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/ajg.2011.64","article-title":"Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis","volume":"106","author":"Khan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0092","first-page":"CD000545","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn\u2019s disease","author":"Chande","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0093","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1155\/2014\/649465","article-title":"Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease","volume":"28","author":"Marshall","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0094","first-page":"CD000067","article-title":"Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn\u2019s disease","author":"Chande","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0095","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s10620-014-3419-5","article-title":"Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn\u2019s disease","volume":"60","author":"Wenzl","year":"2015","journal-title":"Dig Dis Sci"},{"key":"2019071010454862800_CIT0096","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ajg.2013.402","article-title":"The role of thiopurines in reducing the need for surgical resection in Crohn\u2019s disease: a systematic review and meta-analysis","volume":"109","author":"Chatu","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0097","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2036.2010.04330.x","article-title":"Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease","volume":"32","author":"Smith","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"2019071010454862800_CIT0098","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0099","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ajg.2013.451","article-title":"Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis","volume":"109","author":"Ariyaratnam","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0100","volume-title":"Imuran (azathioprine) or Purinethol (mercaptopurine): association with a type of blood cancer - hepatosplenic T-cell lymphoma - for health professionals","author":"Health Canada"},{"key":"2019071010454862800_CIT0101","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"2019071010454862800_CIT0102","first-page":"CD003459","article-title":"Methotrexate for induction of remission in refractory Crohn\u2019s disease","author":"McDonald","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0103","first-page":"2203","article-title":"Methotrexate in chronic active Crohn\u2019s disease: a double-blind, randomized, Israeli multicenter trial","volume":"92","author":"Oren","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0104","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn\u2019s disease: the North American Crohn\u2019s Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"N Engl J Med"},{"key":"2019071010454862800_CIT0105","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/apt.12161","article-title":"Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn\u2019s disease","volume":"37","author":"Wilson","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2019071010454862800_CIT0106","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1365-2036.2003.01614.x","article-title":"Bioavailability of oral vs subcutaneous low-dose methotrexate in patients with Crohn\u2019s disease","volume":"18","author":"Kurnik","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"2019071010454862800_CIT0107","first-page":"CD006884","article-title":"Methotrexate for maintenance of remission in Crohn\u2019s disease","author":"Patel","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0108","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn\u2019s disease: North American Crohn\u2019s Study Group Investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"N Engl J Med"},{"key":"2019071010454862800_CIT0109","first-page":"651","article-title":"Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity","volume":"32","author":"Weinshilboum","year":"1980","journal-title":"Am J Hum Genet"},{"key":"2019071010454862800_CIT0110","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0111","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","article-title":"Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn\u2019s disease: a network meta-analysis","volume":"148","author":"Hazlewood","year":"2015","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0112","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.mayocp.2014.08.019","article-title":"Comparative efficacy of biologic therapy in biologic-naive patients with Crohn disease: a systematic review and network meta-analysis","volume":"89","author":"Singh","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"2019071010454862800_CIT0113","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0114","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn\u2019s disease: a European multicenter trial","volume":"116","author":"D\u2019Haens","year":"1999","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0115","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"2019071010454862800_CIT0116","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0117","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial","volume":"371","author":"D\u2019Haens","year":"2008","journal-title":"Lancet"},{"key":"2019071010454862800_CIT0118","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.3748\/wjg.v20.i39.14479","article-title":"Evaluation of \u201ctop-down\u201d treatment of early Crohn\u2019s disease by double balloon enteroscopy","volume":"20","author":"Fan","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2019071010454862800_CIT0119","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/ecco-jcc\/jjv220","article-title":"Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort","volume":"10","author":"Gecse","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2019071010454862800_CIT0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/17474124.2015.1091308","article-title":"Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study","volume":"9","author":"Jahnsen","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0121","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3109\/00365521.2016.1149883","article-title":"Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn\u2019s disease and ulcerative colitis","volume":"51","author":"Keil","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"2019071010454862800_CIT0122","first-page":"297","article-title":"Switching from Remicade(R) to Remsima(R) is well tolerated and feasible: a prospective, open-label study","volume":"11","author":"Buer","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019071010454862800_CIT0123","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Jorgensen","year":"2017","journal-title":"Lancet"},{"key":"2019071010454862800_CIT0124","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ecco-jcc\/jjw138","article-title":"Patient perspectives on biosimilars: a survey by the European Federation of Crohn\u2019s and Ulcerative Colitis Associations","volume":"11","author":"Peyrin-Biroulet","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019071010454862800_CIT0125","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2013.10.046","article-title":"American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn\u2019s disease","volume":"145","author":"Dassopoulos","year":"2013","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0126","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.crohns.2014.07.003","article-title":"Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn\u2019s disease: a systematic review and meta-analysis","volume":"8","author":"Kopylov","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2019071010454862800_CIT0127","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/apt.13838","article-title":"Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn\u2019s disease or ulcerative colitis who had failed conventional therapy","volume":"45","author":"Colombel","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2019071010454862800_CIT0128","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn\u2019s disease: a prospective, randomized trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2019071010454862800_CIT0129","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn\u2019s disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0131","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0132","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"2019071010454862800_CIT0133","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease: Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"2019071010454862800_CIT0134","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn\u2019s disease patients: a randomized placebo-controlled trial","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0135","first-page":"CD006893","article-title":"Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn\u2019s disease","author":"Behm","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0136","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0137","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0138","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn\u2019s disease","volume":"64","author":"Vande Casteele","year":"2015","journal-title":"Gut"},{"key":"2019071010454862800_CIT0139","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0140","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more cost-effective than dose intensification in patients with Crohn\u2019s disease who lose response to anti-TNF treatment: a randomised, controlled trial","volume":"63","author":"Steenholdt","year":"2014","journal-title":"Gut"},{"key":"2019071010454862800_CIT0141","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/gutjnl-2011-300755","article-title":"Switch to adalimumab in patients with Crohn\u2019s disease controlled by maintenance infliximab: prospective randomised SWITCH trial","volume":"61","author":"Van Assche","year":"2012","journal-title":"Gut"},{"key":"2019071010454862800_CIT0142","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2019071010454862800_CIT0143","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cgh.2016.03.038","article-title":"Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn\u2019s disease","volume":"14","author":"Singh","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0144","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/MIB.0000000000000373","article-title":"Efficacy and safety of natalizumab and vedolizumab for the management of Crohn\u2019s disease: a systematic review and meta-analysis","volume":"21","author":"Chandar","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0145","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn\u2019s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0146","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"2019071010454862800_CIT0147","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0148","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn\u2019s disease: results from the US VICTORY Consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2019071010454862800_CIT0149","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.MIB.0000480052.94783.fd","article-title":"Evidence of mucosal healing in patients with Crohn\u2019s disease treated with open-label vedolizumab: a case series [abstract P-006]","volume":"22","author":"Shafran","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0150","doi-asserted-by":"crossref","first-page":"S804","DOI":"10.1016\/S0016-5085(16)32722-6","article-title":"Mucosal healing and dysplasia surveillance in a large referral center cohort of patients with Crohn\u2019s disease and ulcerative colitis treated with vedolizumab [abstract Mo1880]","volume":"150","author":"Noman","year":"2016","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0151","first-page":"S277","article-title":"Efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with Crohn\u2019s disease from GEMINI 2 [abstract Sa1270]","volume":"148","author":"Colombel","year":"2015","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0152","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/apt.13243","article-title":"Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn\u2019s disease","volume":"42","author":"Rosario","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2019071010454862800_CIT0153","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1873-9946(14)60083-0","article-title":"Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from the GEMINI 1 and 2 studies [abstract DOP058]","volume":"8","author":"Rosario","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2019071010454862800_CIT0154","first-page":"412","article-title":"Long-term efficacy of vedolizumab for Crohn\u2019s disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2019071010454862800_CIT0155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients naive to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0156","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"2019071010454862800_CIT0157","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0158","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"2019071010454862800_CIT0159","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2019071010454862800_CIT0160","first-page":"CD007572","article-title":"Anti-IL-12\/23p40 antibodies for induction of remission in Crohn\u2019s disease","author":"Khanna","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0161","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2015.09.018","article-title":"Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn\u2019s disease refractory to anti-tumor necrosis factor agents","volume":"14","author":"Wils","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0162","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/MIB.0000000000000842","article-title":"Ustekinumab for the treatment of refractory Crohn\u2019s disease: the spanish experience in a large multicentre open-label cohort","volume":"22","author":"Khorrami","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0163","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MIB.0000000000000624","article-title":"Patients with refractory Crohn\u2019s disease successfully treated with ustekinumab","volume":"22","author":"Harris","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0164","first-page":"473","article-title":"Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease","volume":"7","author":"Ghouri","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"key":"2019071010454862800_CIT0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12328-013-0440-8","article-title":"Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials","volume":"7","author":"Fujiya","year":"2014","journal-title":"Clin J Gastroenterol"},{"key":"2019071010454862800_CIT0166","first-page":"CD006634","article-title":"Probiotics for induction of remission in Crohn\u2019s disease","author":"Butterworth","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0167","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1007\/s10620-007-0171-0","article-title":"A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn\u2019s disease","volume":"53","author":"Rahimi","year":"2008","journal-title":"Dig Dis Sci"},{"key":"2019071010454862800_CIT0168","doi-asserted-by":"crossref","first-page":"S240","DOI":"10.1017\/S0007114512001626","article-title":"Omega-3 fatty acids and inflammatory bowel diseases: a systematic review","volume":"107","author":"Cabre","year":"2012","journal-title":"Br J Nutr"},{"key":"2019071010454862800_CIT0169","first-page":"CD006320","article-title":"Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn\u2019s disease","author":"Lev-Tzion","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0170","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cgh.2013.04.034","article-title":"Cannabis induces a clinical response in patients with Crohn\u2019s disease: a prospective placebo-controlled study","volume":"11","author":"Naftali","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0171","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/01.MIB.0000440982.79036.d6","article-title":"Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn\u2019s disease","volume":"20","author":"Storr","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0172","first-page":"CD010410","article-title":"Low dose naltrexone for induction of remission in Crohn\u2019s disease","author":"Segal","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0173","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/gut.2005.080887","article-title":"Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation","volume":"55","author":"Philippe","year":"2006","journal-title":"Gut"},{"key":"2019071010454862800_CIT0174","first-page":"CD007348","article-title":"Glutamine for induction of remission in Crohn\u2019s disease","author":"Akobeng","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0175","first-page":"CD005984","article-title":"Enteral nutrition for maintenance of remission in Crohn\u2019s disease","author":"Akobeng","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2019071010454862800_CIT0176","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/1756283X15578607","article-title":"Specialized enteral nutrition therapy in Crohn\u2019s disease patients on maintenance infliximab therapy: a meta-analysis","volume":"8","author":"Nguyen","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"2019071010454862800_CIT0177","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn\u2019s disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"2019071010454862800_CIT0178","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0016-5085(90)90002-I","article-title":"Clinical, biological, and endoscopic picture of attacks of Crohn\u2019s disease: evolution on prednisolone\u2014Groupe d\u2019Etude Therapeutique des Affections Inflammatoires Digestives","volume":"98","author":"Modigliani","year":"1990","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0179","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2013.06.009","article-title":"Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn\u2019s disease","volume":"145","author":"Panes","year":"2013","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0180","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/j.gastro.2013.04.048","article-title":"Early administration of azathioprine vs conventional management of Crohn\u2019s disease: a randomized controlled trial","volume":"145","author":"Cosnes","year":"2013","journal-title":"Gastroenterology"},{"key":"2019071010454862800_CIT0181","first-page":"981","article-title":"Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience","volume":"52","author":"Macaluso","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"2019071010454862800_CIT0182","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2014.02.026","article-title":"Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease","volume":"12","author":"Lopez","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019071010454862800_CIT0183","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","article-title":"Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer","volume":"63","author":"Beaugerie","year":"2014","journal-title":"Gut"},{"key":"2019071010454862800_CIT0184","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1097\/MIB.0000000000000923","article-title":"Experts opinion on the practical use of azathioprine and 6-mercaptopurine in inflammatory bowel disease","volume":"22","author":"Mottet","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2019071010454862800_CIT0185","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1007\/s12325-017-0545-4","article-title":"Predicting pre-emptive discussions of biologic treatment: results from an openness and preference survey of inflammatory bowel disease patients and their prescribers","volume":"34","author":"Kariburyo","year":"2017","journal-title":"Adv Ther"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcag\/article-pdf\/2\/3\/e1\/28923475\/gwz019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T14:46:47Z","timestamp":1562770007000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/2\/3\/e1\/5530651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":185,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,7,10]]},"published-print":{"date-parts":[[2019,7,10]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwz019","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"value":"2515-2084","type":"print"},{"value":"2515-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2018,7,10]]}}}